Evidence map›Paper›PMID 33034797›Full record

ArticleJournal of molecular histology2020

Long non-coding RNAs as targets for immunosuppressive drug teriflunomide in anti-cancer potential for hepatocellular carcinoma.

Yinkai Xu, Daoming Shen, Jianxia Liu, Xiaolan Xu, Junhao Tu, Lei Qin, Liyang Jiang, Haixin Qian, Fengbao Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yinkai XuDepartment of General Surgery, The First Affiliated Hospital of Soochow University, No. 188, Shi Zi Road, Suzhou, 215006, China.
Daoming ShenDepartment of Gastroenterology, Xiangcheng People's Hospital, Suzhou, 215131, China.
Jianxia LiuDepartment of General Surgery, The First Affiliated Hospital of Soochow University, No. 188, Shi Zi Road, Suzhou, 215006, China.
Xiaolan XuDepartment of Gastroenterology, Xiangcheng People's Hospital, Suzhou, 215131, China.
Junhao TuDepartment of General surgery, Suzhou Wuzhong People's Hospital, Suzhou, 215128, People's Republic of China.
Lei QinDepartment of General Surgery, The First Affiliated Hospital of Soochow University, No. 188, Shi Zi Road, Suzhou, 215006, China.
Liyang JiangDepartment of Intensive Care Unit, The Affiliated Suzhou Hospital of Nanjing Medical University, 242 Guangji Road, Suzhou, Jiangsu, People's Republic of China. jiangliyangff@sina.com.
Haixin QianDepartment of General Surgery, The First Affiliated Hospital of Soochow University, No. 188, Shi Zi Road, Suzhou, 215006, China. qianhaixin1@hotmail.com.
Fengbao GuoDepartment of Emergency Medicine, The First Affiliated Hospital of Soochow University, No. 188, Shi Zi Road, Suzhou, 215006, People's Republic of China. guofb2008@163.com.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNNanjing Medical University · CNThe Fifth People’s Hospital of Suzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Because of the relatively chemotherapy-refractory nature of HCC and significant potential poor hepatic reserve, chemotherapy has not been used consistently in the treatment of HCC. Effective new drugs for HCC are urgently needed. Teriflunomide, which was approved for the treatment of relapsing forms of multiple sclerosis (MS), has been identified as a potential antineoplastic drug. Long noncoding RNAs (lncRNAs) are a novel class of RNA molecules defined as transcripts longer than 200 nucleotides that lack protein coding potential. In this study, we investigated the ability of teriflunomide to act as an antineoplastic drug by examining the effects of teriflunomide treatment on HCC cells. Teriflunomide strongly inhibited the proliferation of HCC cells, induced cell apoptosis and induced cell accumulation in S phases of the cell cycle. LncRNA and mRNA expression profiles of HCC cells treated with teriflunomide compared with controls were performed by using microarray analysis. For comparison, the differentially expressed mRNAs were annotated by using gene ontology (GO) and pathway analyses. The microarray revealed that 2085 lncRNAs and 1561 mRNAs differed in the cells treated with teriflunomide compared with controls. Several GO terms including protein folding, mitochondrial outer membrane, transmembrane receptor protein phosphatase activity, negative regulation of cellular biosynthetic process, DNA packaging complex, and receptor signaling protein activity were enriched in gene lists, suggesting a potential correlation with the action mechanism of teriflunomide. Pathway analysis then demonstrated that JAK-STAT signaling pathway may play important roles in the cell apoptosis induced by teriflunomide. Co-expression network analysis indicated that a number of lncRNAs and mRNAs were included in the co-expression network, and p34710_v4 is the lncRNA with highest degree. Then the mRNAs associated with those differentially expressed lncRNAs were also annotated by using gene ontology (GO) and pathway analyses. The pathway analyses shows that teriflunomide significantly inhibited cell proliferation and promoted cell apoptosis partly by participating in Wnt signaling pathways. These findings suggest that teriflunomide could be a potential drug for chemotherapy and molecularly targeted therapies of HCC.

Indexed as

Antineoplastic AgentsApoptosisCarcinoma, HepatocellularCell Line, TumorCell ProliferationComputational BiologyCrotonatesGene Expression ProfilingGene Expression Regulation, NeoplasticGene OntologyHumansHydroxybutyratesImmunosuppressive AgentsLiver NeoplasmsNitrilesRNA InterferenceAntineoplastic AgentsCrotonatesHydroxybutyratesImmunosuppressive AgentsNitrilesRNA, Long NoncodingRNA, MessengerteriflunomideToluidinesHepatocellular carcinomaLong non-coding RNAsMicroarrayTeriflunomide

Identifiers

PMID33034797
OpenAlexW3092155470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.